Navigation Links
Isis Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Date:9/14/2010

CARLSBAD, Calif., Sept. 14 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at UBS' Global Life Sciences Conference on Tuesday, September 21, 2010 at 4:00 p.m. ET at the Grand Hyatt New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 23 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
2. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
3. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
4. Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
5. Meditrina Pharmaceuticals, Inc. Announces Allowance of Patent for Treatment of Endometriosis
6. Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period
7. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
8. Access Pharmaceuticals to Present At Rodman & Renshaw Annual Global Investment Conference in New York City
9. MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial
10. Isis Pharmaceuticals to Present at the Stifel Nicolaus 2010 Healthcare Conference
11. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" ... developing and commercializing proven cancer therapies in new ... from its Phase I/II clinical trial of  VAL-083 ... the most common and deadly form of human ...
(Date:6/1/2015)... LONDON , June 1, 2015 ... carcinoma segment will drive growth , says   ... Cell Lung Cancer (NSCLC) treatment market will be driven primarily ... and squamous cell treatment settings, which either replace or combine ... GBI Research - Non-Small Cell Lung Cancer Market to ...
(Date:6/1/2015)... DUBLIN , May 29, 2015 ... the addition of the "Global Power Wheelchair ... The Global Power Wheelchair Industry Report ... the current state of the power wheelchair industry. ... of the industry including definitions, classifications, applications and ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 2New Therapies to Enhance Increasingly Competitive Non-Small Cell Lung Cancer Treatment Market 3Global Power Wheelchair Industry Trends 2015-2020 2
... 2011 Alere Inc. (NYSE: ALR ), ... health at home through the merger of rapid diagnostics and health ... 31, 2010. Financial results for the fourth quarter ... the fourth quarter of 2010, compared to $546.2 million for the ...
... 2011 Cepheid (Nasdaq: CPHD ) today ... following investor conferences, and invited investors to participate via ... 1, 2011 at 8.30 a.m. Eastern TimeRBC Capital Markets, ... 11.00 a.m. Eastern TimeTo access the live webcasts for ...
Cached Medicine Technology:Alere Inc. Announces Fourth Quarter 2010 Results 2Alere Inc. Announces Fourth Quarter 2010 Results 3Alere Inc. Announces Fourth Quarter 2010 Results 4Alere Inc. Announces Fourth Quarter 2010 Results 5Alere Inc. Announces Fourth Quarter 2010 Results 6Alere Inc. Announces Fourth Quarter 2010 Results 7Alere Inc. Announces Fourth Quarter 2010 Results 8Alere Inc. Announces Fourth Quarter 2010 Results 9Alere Inc. Announces Fourth Quarter 2010 Results 10Alere Inc. Announces Fourth Quarter 2010 Results 11Alere Inc. Announces Fourth Quarter 2010 Results 12Alere Inc. Announces Fourth Quarter 2010 Results 13Alere Inc. Announces Fourth Quarter 2010 Results 14Alere Inc. Announces Fourth Quarter 2010 Results 15Alere Inc. Announces Fourth Quarter 2010 Results 16Alere Inc. Announces Fourth Quarter 2010 Results 17Alere Inc. Announces Fourth Quarter 2010 Results 18Alere Inc. Announces Fourth Quarter 2010 Results 19Cepheid to Webcast Upcoming Financial Presentations 2
(Date:6/2/2015)... 02, 2015 Join us for a new ... in Honor of Rhonda Martin , who overcame her brain ... dedicated their resources to raising awareness and funds for brain ... awareness in hopes that there will be one less case ... welcome and encouraged to join the 1st Anniversary Awareness ...
(Date:6/2/2015)... 2015 Pacifica Graduate Institute ... by current and former students to honor the memory ... from 2002 until his death in 2013. His students ... of feeling, as well as his passion for politics, ... an analyst, teacher, and writer were felt in his ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 “We want men ... ultraviolet (UV) sun rays”, states Marta Phillips, owner of SunGrubbies.com, ... men’s sun hats and sun accessories that work well for ... not immediately evident. Sometimes sun damage can take up to ... neck are prime areas for skin cancer to occur. ...
(Date:6/1/2015)... (PRWEB) June 02, 2015 The ... Lynn Lester as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... Lester with this prestigious award,” said NAPW President Star ...
(Date:6/1/2015)... June 02, 2015 The National ... Ditmyer as a 2015-2016 inductee into the NAPW ... recognized with this prestigious distinction for leadership in academics. ... Local Chapters, NAPW is the nation’s leading networking organization ... Marcia with this important distinction,” said NAPW President Star ...
Breaking Medicine News(10 mins):Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 2Health News:Pacifica Graduate Institute - Mythological Studies Students Establish Memorial Scholarship to Honor Dr. V. Walter Odajnyk 3Health News:It is Time to Show Father Who Knows Best, Says SunGrubbies.com, a Leading Online Sun Protection Retailer 2Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Marcia Ditmyer, Vice President of Academy for Academic Leadership, Into its VIP Professional Woman of the Year Circle 2
... Researchers from Japan have recently demonstrated the first evidence ... ,Fungal secondary metabolites such as gliotoxin, an ... Aspergillus//, possess immunosuppressive activities and have been thought to ... humans. ,Mast cells play a key role ...
... who are prone to backaches, insomnia and eyesight problems ... treatment protocol for treating software professionals would be outlined ... Thrissur next month, said eminent ayurveda expert Neelakantan Mooss ... Thaikkattu Mooss Vaidyaratnam Oushadhasala, said detailed examinations had been ...
... from National Cancer Institute, US is to start testing their ... drug metabolize, enzyme kinetics and drug action mechanisms in dogs ... ,Dr. Chand Khanna, Veterinary Oncologist said, “It turns out that ... represented in dogs and the dogs will help us prioritize ...
... new research conducted in Helsinki, Finland, gluten-free diet ... adolescents with coeliac disease.,Coeliac disease in adolescents has ... and disruptive behavioural disorders, particularly in the phase ... 9 adolescents with coeliac disease, aged 12 to ...
... the first of its kind, French researchers report of ... with attention-deficit/hyperactivity disorder//. , The authors, ... present the case report of a 3-year-old child, who ... and sleep problems. ,According to the parents, ...
... is expected to get a major boost with the central ... in the interior regions//. ,Health Minister Anbumani ... northeastern states in Assam's main city of Guwahati with a ... adequate nursing staff. ,"We shall make it mandatory for ...
Cached Medicine News:Health News:Gluten-Free Diet May Alleviate Psychiatric Symptoms In Adolescents 2Health News:Iron Supplementation Aid In Relief From Attention-Deficit/Hyperactivity Disorder 2
... ACL 8000 is an easy-to-use, automated system ... array of assays for managing hemostatic disordersincluding ... S. Also offers reflex and rerun testing ... it's backed by our high-quality service to ...
... System is designed to provide excellent capture ... carotid stenting interventions. The ACCUNET is a ... utilizes rapid exchange technology so that the ... catheter manipulations. It is available in both ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Lancet cut ultra sharp tip for low penetration resistance. Low noise and impedance level giving you a clear and reliable signal. Stainless steel needle, color coded attached lead wires. Needles sold ...
Medicine Products: